| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Exhibit | Description | |||||||
| 99.1 | ||||||||
| 104.1 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
| ZOSANO PHARMA CORPORATION | |||||||||||||||||
| Date: May 13, 2022 | By: | /s/ Christine Matthews | |||||||||||||||
| Name: Christine Matthews | |||||||||||||||||
| Title: Chief Financial Officer | |||||||||||||||||
March 31, 2022 | December 31, 2021 | ||||||||||
| (unaudited) | |||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ 13,529 | $ 11,043 | |||||||||
| Accounts receivable | 91 | 146 | |||||||||
| Prepaid expenses and other current assets | 2,012 | 420 | |||||||||
| Total current assets | 15,632 | 11,609 | |||||||||
| Restricted cash | 455 | 455 | |||||||||
| Property and equipment, net | 7,922 | 32,557 | |||||||||
| Operating lease right-of-use assets | 2,436 | 3,769 | |||||||||
| Total assets | $ 26,445 | $ 48,390 | |||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ 3,720 | $ 2,120 | |||||||||
| Accrued compensation | 475 | 1,767 | |||||||||
| Build-to-suit obligation, current portion, net of debt issuance costs and discount | 1,739 | 3,822 | |||||||||
| Operating lease liabilities, current portion | 1,642 | 1,606 | |||||||||
| Other accrued liabilities | 2,154 | 1,818 | |||||||||
| Total current liabilities | 9,730 | 11,133 | |||||||||
| Build-to-suit obligation, long-term portion, net of debt issuance costs and discount | — | 970 | |||||||||
| Operating lease liabilities, long-term portion | 2,662 | 3,081 | |||||||||
| Other long-term liabilities | — | 231 | |||||||||
| Total liabilities | 12,392 | 15,415 | |||||||||
| Stockholders’ equity: | |||||||||||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of March 31, 2022 and December 31, 2021 | — | — | |||||||||
| Common stock, $0.0001 par value; 250,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 4,902,260 and 3,434,451 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | — | — | |||||||||
| Additional paid-in capital | 409,577 | 395,090 | |||||||||
| Accumulated deficit | (395,524) | (362,115) | |||||||||
Total stockholders’ equity | 14,053 | 32,975 | |||||||||
| Total liabilities and stockholders’ equity | $ 26,445 | $ 48,390 | |||||||||
| Three Months Ended March 31, | |||||||||||
| 2022 | 2021 | ||||||||||
| Service revenue | $ 132 | $ 258 | |||||||||
| Operating expenses: | |||||||||||
| Cost of service revenue | 86 | 162 | |||||||||
| Research and development | 4,481 | 5,330 | |||||||||
| General and administrative | 2,942 | 2,814 | |||||||||
| Impairment loss | 25,941 | — | |||||||||
Total operating expenses | 33,450 | 8,306 | |||||||||
| Loss from operations | (33,318) | (8,048) | |||||||||
| Other income (expense): | |||||||||||
| Interest income | 2 | 1 | |||||||||
| Interest expense | (73) | (97) | |||||||||
| Other income (expense), net | (20) | 2 | |||||||||
Loss before provision for income taxes | (33,409) | (8,142) | |||||||||
Provision for income taxes | — | — | |||||||||
| Net loss | $ (33,409) | $ (8,142) | |||||||||
| Net loss per common share – basic and diluted | $ (7.86) | $ (2.73) | |||||||||
| Weighted-average common shares used in computing net loss per common share – basic and diluted | 4,248 | 2,981 | |||||||||
Cover Page |
Mar. 11, 2021 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Document Period End Date | May 10, 2022 |
| Entity Registrant Name | ZOSANO PHARMA CORPORATION |
| Entity Incorporation, State or Country Code | DE |
| Entity File Number | 001-36570 |
| Entity Tax Identification Number | 45-4488360 |
| Entity Address, Address Line One | 34790 Ardentech Court |
| Entity Address, City or Town | Fremont |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94555 |
| City Area Code | 510 |
| Local Phone Number | 745-1200 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.0001 par value |
| Trading Symbol | ZSAN |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Flag | false |
| Entity Central Index Key | 0001587221 |
-8?20$3;8T.P
M6BP^0"X99K>]9!:G